FGP
HUMA icon

Freestone Grove Partners’s Humacyte HUMA Stock Holding History

Freestone Grove Partners’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-38,899
Closed -$196K – 683
2024
Q4 		$196K Buy
+38,899
New +$192K ﹤0.01% 536

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Freestone Grove Partners's HUMA Position: Q1 2025 in Review

Freestone Grove Partners sold out of Humacyte (HUMA) in Q1 2025, closing a stake of 38,899 shares — an estimated $196K sold.

Freestone Grove Partners first reported a position in HUMA in Q4 2024 and held it in 1 quarter. The position peaked at $196K in Q4 2024. 168 funds tracked by Wall St. Rank hold HUMA as of Q1 2025.

  • Freestone Grove Partners reported no remaining Humacyte position as of Q1 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 38,899 Humacyte shares in Q1 2025, an estimated $196K.
  • Freestone Grove Partners first reported a position in Humacyte in Q4 2024 and held it in 1 quarter.
  • Freestone Grove Partners's Humacyte position peaked at $196K in Q4 2024.
  • 168 funds tracked by Wall St. Rank held Humacyte as of Q1 2025.

Based on Freestone Grove Partners's 13F filing for Q1 2025, filed 15 May 2025.